sulfathiazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-infectives, sulfonamides | 2527 | 72-14-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 12, 1945 | FDA | ORTHO MCNEIL PHARM |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Swollen joint count increased | 93.30 | 58.22 | 48 | 4681 | 36006 | 63448287 |
| Rheumatic fever | 90.71 | 58.22 | 50 | 4679 | 43061 | 63441232 |
| Rheumatoid factor positive | 88.82 | 58.22 | 63 | 4666 | 84343 | 63399950 |
| Anti-cyclic citrullinated peptide antibody positive | 87.48 | 58.22 | 71 | 4658 | 116141 | 63368152 |
| Duodenal ulcer perforation | 86.97 | 58.22 | 63 | 4666 | 87146 | 63397147 |
| Muscle injury | 83.50 | 58.22 | 55 | 4674 | 65290 | 63419003 |
| Folliculitis | 79.83 | 58.22 | 55 | 4674 | 70262 | 63414031 |
| Helicobacter infection | 79.06 | 58.22 | 61 | 4668 | 92724 | 63391569 |
| Irritable bowel syndrome | 74.21 | 58.22 | 56 | 4673 | 82356 | 63401937 |
| Wound | 74.03 | 58.22 | 75 | 4654 | 163188 | 63321105 |
| Discomfort | 70.66 | 58.22 | 74 | 4655 | 167300 | 63316993 |
| Hand deformity | 68.20 | 58.22 | 71 | 4658 | 159386 | 63324907 |
| Ill-defined disorder | 68 | 58.22 | 53 | 4676 | 81702 | 63402591 |
| Pemphigus | 66.68 | 58.22 | 75 | 4654 | 183651 | 63300642 |
| Glossodynia | 66.59 | 58.22 | 74 | 4655 | 178802 | 63305491 |
| Blood cholesterol increased | 65.60 | 58.22 | 55 | 4674 | 93977 | 63390316 |
| Impaired healing | 63.45 | 58.22 | 56 | 4673 | 102486 | 63381807 |
| Blister | 63.17 | 58.22 | 62 | 4667 | 129752 | 63354541 |
| Pericarditis | 62.46 | 58.22 | 62 | 4667 | 131517 | 63352776 |
| Hepatic enzyme increased | 59.20 | 58.22 | 74 | 4655 | 202254 | 63282039 |
| Synovitis | 58.94 | 58.22 | 71 | 4658 | 186847 | 63297446 |
| Systemic lupus erythematosus | 58.89 | 58.22 | 75 | 4654 | 208843 | 63275450 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Duodenal ulcer perforation | 54.28 | 50.28 | 30 | 2305 | 66181 | 79675872 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D06BA02 | DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE CHEMOTHERAPEUTICS FOR TOPICAL USE Sulfonamides |
| ATC | J01EB07 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Short-acting sulfonamides |
| MeSH PA | D000890 | Anti-Infective Agents |
| CHEBI has role | CHEBI:35441 | antiinfective agents |
| CHEBI has role | CHEBI:35703 | Xenobiotic |
| CHEBI has role | CHEBI:50502 | dihydropteroate synthase inhibitors |
| CHEBI has role | CHEBI:78298 | environmental contaminants |
| CHEBI has role | CHEBI:88188 | allergenic drug |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Vulvovaginitis | indication | 53277000 | DOID:2273 |
| Gardnerella Vaginalis Bacterial Vaginosis | indication | ||
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Deficiency of glucose-6-phosphate dehydrogenase | contraindication | 124134002 | DOID:2862 |
| Disease of blood AND/OR blood-forming organ | contraindication | 191124002 | DOID:74 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Porphyria | contraindication | 418470004 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.16 | acidic |
| pKa2 | 2.48 | Basic |
| pKa3 | 1.61 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Endothelin-1 receptor | GPCR | IC50 | 4.16 | WOMBAT-PK | |||||
| Dihydropteroate synthase | Enzyme | INHIBITOR | IC50 | 5.60 | CHEMBL | CHEMBL | |||
| Endothelin-1 receptor | GPCR | IC50 | 4.16 | CHEMBL | |||||
| Transcriptional activator protein LasR | Unclassified | IC50 | 5.05 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018558 | VUID |
| N0000178992 | NUI |
| D01047 | KEGG_DRUG |
| 4018558 | VANDF |
| C0038722 | UMLSCUI |
| CHEBI:9337 | CHEBI |
| YTZ | PDB_CHEM_ID |
| CHEMBL437 | ChEMBL_ID |
| DB06147 | DRUGBANK_ID |
| D000077589 | MESH_DESCRIPTOR_UI |
| 5340 | PUBCHEM_CID |
| 12699 | IUPHAR_LIGAND_ID |
| 428 | INN_ID |
| Y7FKS2XWQH | UNII |
| 10193 | RXNORM |
| 5529 | MMSL |
| 002815 | NDDF |
| 16867004 | SNOMEDCT_US |
| 387093005 | SNOMEDCT_US |
Pharmaceutical products:
None